Roche
Roche pays $8.3bn for InterMune
August 26, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, Genentech, IPF, Illumina, InterMune, Roche
Roche has stumped up $8.3 billion in cash to pay for US biotech firm InterMune and will gain access to …
Storm brewing over Roche cancer drug price
August 8, 2014Medical Communications, Research and Development, Sales and Marketing Cancer, Haslam, Kadcyla, NICE, Roche, Yervoy, rejection
The Breakthrough Breast Cancer charity and England’s drug pricing watchdog NICE have both attacked Roche for not lowering the price …
Roche gains new licence for blockbuster oncology drug
August 6, 2014Research and Development, Sales and Marketing EC, Roche, avastin, ovarian cancer
Roche’s blockbuster cancer treatment Avastin now has a new European licence to treat women with a certain type of ovarian …
Blood cancer injection given green light
August 5, 2014Research and Development, Sales and Marketing MabThera, Roche, follicular lymphoma and small lymphocytic lymphoma
Roche has launched a new injection formulation of its blood cancer drug MabThera (rituximab) to treat patients with follicular lymphoma, …
Gene silencing back on the books for Roche
August 5, 2014Research and Development, Sales and Marketing RNA, Roche, Santaris, gene silencing
Roche will pay $450 million to acquire the RNA specialist firm Santaris Pharma in order to once again begin research …
Roche’s blood cancer drug gains EU approval
July 29, 2014Research and Development, Sales and Marketing CLL, Cancer, Gilead, Janssen, Roche
The European Commission has approved Roche’s new leukaemia drug Gazyvaro (obinutuzumab) as competition for the blood cancer market heats up. …
GSK melanoma drugs beat rival in new study
July 18, 2014Sales and Marketing GSK, Roche, Tafinlar, Yervoy, Zelboraf, mekinist, melanoma
GlaxoSmithKline’s new combination melanoma treatment has bested Roche’s established oncology drug Zelboraf when treating patients with the deadliest form of …
FDA speedy review for new Avastin licence
July 16, 2014Research and Development, Sales and Marketing Cancer, Roche, avastin, cervical cancer
The FDA has granted priority review status for Roche’s Avastin (bevacizumab) plus chemotherapy in women with persistent, recurrent or metastatic …
Roche combination drug for melanoma impresses
July 14, 2014Research and Development, Sales and Marketing GSK, Roche, Yervoy, braf, mekinist. MEK, melanoma
Roche’s investigational melanoma drug cobimetinib has helped late-stage patients live longer when used in combination with its established skin cancer …
Genentech to buy Seragon
July 3, 2014Sales and Marketing Genentech, Roche, breast cancer, oncology, serds
Roche subsidiary Genentech is to pay around $1.7 billion for biotech firm Seragon Pharmaceuticals to secure its portfolio of potential …
Roche to launch new MS collaboration
June 23, 2014Research and Development, Sales and Marketing MS, Roche, inception sciences, multiple sclerosis, versant ventures
Roche has launched a new research collaboration to investigate ways of reversing the debilitating nerve damage caused by multiple sclerosis …
Italy eyes €1.2 billion pharma fine
May 30, 2014Sales and Marketing Novartis, Roche, avastin, off label, wet and
Italy’s health ministry says it is looking for €1.2 billion in damages from Roche and Novartis over claims that the …
IT director Chris Roche joins Aridhia
May 30, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing EMC, IT, Roche, aridhia
Health tech informatics firm Aridhia has appointed Chris Roche to a newly-created post on its executive team as chief commercial …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
